Breaking News

Veraxa Biotech and Indivumed to Jointly Develop Precision Oncology Antibody Drugs

Aim to discover new possibilities for cancer treatment in the shortest-possible time.

Author Image

By: Charlie Sternberg

Associate Editor

Veraxa Biotech GmbH and Indivumed GmbH have entered an agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for colorectal cancer. The targets have been identified by Indivumed’s discovery solution platform nRavel. The antibody development and commercialization will be performed by Indivumed’s subsidiary, Ix Therapeutics.   Veraxa Biotech GmbH is a pioneer in microfluidic technology for the screening of antibodies with modulatory function o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters